PIK3CA and Hyperglycemia: Pan-PI3K inhibitors (e.g., copanlisib) broadly target α, β, γ, and δ isoforms, achieving pathway suppression but often incurring dose-limiting toxicities such as hyperglycemia and hepatotoxicity due to ubiquitous PI3K expression in normal tissues.